PDF herunterladen
Semin Thromb Hemost 2021; 47(01): 074-083
DOI: 10.1055/s-0040-1718869
Review Article

Outcome of Major Hemorrhage at a Major Cardiothoracic Center in Patients with Activated Major Hemorrhage Protocol versus Nonactivated Protocol

Kathryn W. Chang
1   Department of Haematology, Imperial College London, London, United Kingdom
,
Steve Owen
2   Department of Haematology, Royal Brompton Hospital, London, United Kingdom
,
Michaela Gaspar
2   Department of Haematology, Royal Brompton Hospital, London, United Kingdom
,
Mike Laffan
1   Department of Haematology, Imperial College London, London, United Kingdom
,
Deepa R. J. Arachchillage
1   Department of Haematology, Imperial College London, London, United Kingdom
2   Department of Haematology, Royal Brompton Hospital, London, United Kingdom
› Institutsangaben
› Weitere Informationen
    Lizenzen und Reprints

Abstract

This study aimed to determine the impact of major hemorrhage (MH) protocol (MHP) activation on blood administration and patient outcome at a UK major cardiothoracic center. MH was defined in patients (> 16 years) as those who received > 5 units of red blood cells (RBCs) in < 4 hours, or > 10 units in 24 hours. Data were collected retrospectively from patient electronic records and hospital transfusion databases recording issue of blood products from January 2016 to December 2018. Of 134 patients with MH, 24 had activated MHP and 110 did not have activated MHP. Groups were similar for age, sex, baseline hemoglobin, platelet count, coagulation screen, and renal function with no difference in the baseline clinical characteristics. The total number of red cell units (median and [IQR]) transfused was no different in the patients with activated (7.5 [5–11.75]) versus nonactivated (9 [6–12]) MHP (p = 0.35). Patients in the nonactivated MHP group received significantly higher number of platelet units (median: 3 vs. 2, p = 0.014), plasma (median: 4.5 vs. 1.5, p = 0.0007), and cryoprecipitate (median: 2 vs. 1, p = 0.008). However, activation of MHP was associated with higher mortality at 24 hours compared with patients with nonactivation of MHP (33.3 vs. 10.9%, p = 0.005) and 30 days (58.3 vs. 30.9%, p = 0.01). The total RBC and platelet (but not fresh frozen plasma [FFP]) units received were higher in deceased patients than in survivors. Increased mortality was associated with a higher RBC:FFP ratio. Only 26% of patients received tranexamic acid and these patients had higher mortality at 30 days but not at 24 hours. Deceased patients at 30 days had higher levels of fibrinogen than those who survived (median: 2.4 vs. 1.8, p = 0.01). Patients with activated MHP had significantly higher mortality at both 24 hours and 30 days despite lack of difference in the baseline characteristics of the patients with activated MHP versus nonactivated MHP groups. The increased mortality associated with a higher RBC:FFP ratio suggests dilutional coagulopathy may contribute to mortality, but higher fibrinogen at baseline was not protective.

Keywords

major hemorrhage - tranexamic acid - fibrinogen - mortality - red blood cells - fresh frozen plasma

Authors' Contributions

D.R.J.A. was involved in the study concept, design, analysis, interpretation of data, and preparation of the first draft and revising the manuscript. K.C. was involved in the data collection, analysis, interpretation of the data, and writing the first draft of the manuscript. M.G. and S.O. supported the data collection and revision of the manuscript. M.L. was involved in the interpretation of the data and the revision of the manuscript. All authors approved the final manuscript.




Publikationsverlauf

Artikel online veröffentlicht:
01. Februar 2021

© 2021. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Stanworth SJ, Davenport R, Curry N. et al. Mortality from trauma haemorrhage and opportunities for improvement in transfusion practice. Br J Surg 2016; 103 (04) 357-365
    CrossrefPubMedGoogle Scholar
  • 2 Serraino GF, Murphy GJ. Routine use of viscoelastic blood tests for diagnosis and treatment of coagulopathic bleeding in cardiac surgery: updated systematic review and meta-analysis. Br J Anaesth 2017; 118 (06) 823-833
    CrossrefPubMedGoogle Scholar
  • 3 Ranucci M, Baryshnikova E, Castelvecchio S, Pelissero G. Surgical and Clinical Outcome Research (SCORE) Group. Major bleeding, transfusions, and anemia: the deadly triad of cardiac surgery. Ann Thorac Surg 2013; 96 (02) 478-485
    CrossrefPubMedGoogle Scholar
  • 4 Stainsby D, MacLennan S, Thomas D, Isaac J, Hamilton PJ. British Committee for Standards in Haematology. Guidelines on the management of massive blood loss. Br J Haematol 2006; 135 (05) 634-641
    CrossrefPubMedGoogle Scholar
  • 5 Winearls J, Mitra B, Reade MC. Haemotherapy algorithm for the management of trauma-induced coagulopathy: an Australian perspective. Curr Opin Anaesthesiol 2017; 30 (02) 265-276
    CrossrefPubMedGoogle Scholar
  • 6 NPSA. Rapid Response Report NPSA/2010/017. The transfusion of blood and blood components. [NPSA/2010/RRR017]. 2010;(October):14960. Available at: http://www.nrls.npsa.nhs.uk/EasySiteWeb/getresource.axd?AssetID=83688 . Accessed June 30, 2020
    PubMedGoogle Scholar
  • 7 Hunt BJ, Allard S, Keeling D, Norfolk D, Stanworth SJ, Pendry K. British Committee for Standards in Haematology. A practical guideline for the haematological management of major haemorrhage. Br J Haematol 2015; 170 (06) 788-803
    CrossrefPubMedGoogle Scholar
  • 8 Balvers K, Coppens M, van Dieren S. et al. Effects of a hospital-wide introduction of a massive transfusion protocol on blood product ratio and blood product waste. J Emerg Trauma Shock 2015; 8 (04) 199-204
    CrossrefPubMedGoogle Scholar
  • 9 Cotton BA, Gunter OL, Isbell J. et al. Damage control hematology: the impact of a trauma exsanguination protocol on survival and blood product utilization. J Trauma 2008; 64 (05) 1177-1182 , discussion 1182–1183
    CrossrefPubMedGoogle Scholar
  • 10 Young PP, Cotton BA, Goodnough LT. Massive transfusion protocols for patients with substantial hemorrhage. Transfus Med Rev 2011; 25 (04) 293-303
    CrossrefPubMedGoogle Scholar
  • 11 Roberts I, Shakur H, Afolabi A. et al; CRASH-2 collaborators. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet 2011; 377 (9771): 1096-1101, 1101.e1–1101.e2
    CrossrefPubMedGoogle Scholar
  • 12 Dallaku K, Shakur H, Roberts I. et al. Effects of tranexamic acid on platelet function and thrombin generation (ETAPlaT): WOMAN trial sub-study. Wellcome Open Res 2016; 1: 29
    CrossrefPubMedGoogle Scholar
  • 13 Green L, Tan J, Grist C, Kaur M, MacCallum P. Aetiology and outcome of massive transfusion in two large London teaching hospitals over a 3-year period (2012-2014). Transfus Med 2017; 27 (05) (Suppl. 05) 342-347
    CrossrefPubMedGoogle Scholar
  • 14 NHS Blood and Transplant. 2018 National Comparative Audit of the Management of Major Haemorrhage. Joint United Kingdom Blood Transfusion and Tissue Transplantation Services Professional Advisory Committee. Published 2018. Accessed May 22, 2019 at: https://nhsbtdbe.blob.core.windows.net/umbraco-assets-corp/19130/2018-major-haemorrhage-audit-full-report.pdf
    PubMedGoogle Scholar
  • 15 Dargère M, Langlais M-L, Gangloff C, Léostic C, Le Niger C, Ozier Y. Implementation and evaluation of a major haemorrhage protocol in the Emergency Department Resuscitation Area in the University-affiliated Hospital of Brest (France). Transfus Clin Biol 2019; 26 (04) 309-315
    CrossrefPubMedGoogle Scholar
  • 16 Khan S, Allard S, Weaver A, Barber C, Davenport R, Brohi K. A major haemorrhage protocol improves the delivery of blood component therapy and reduces waste in trauma massive transfusion. Injury 2013; 44 (05) 587-592
    CrossrefPubMedGoogle Scholar
  • 17 Hargreaves J. Developing and implementing a protocol for major haemorrhage. Br J Nurs 2014; 23 (21) 1140-1145
    CrossrefPubMedGoogle Scholar
  • 18 Gutierrez G, Reines HD, Wulf-Gutierrez ME. Clinical review: hemorrhagic shock. Crit Care 2004; 8 (05) 373-381
    CrossrefPubMedGoogle Scholar
  • 19 Santos AA, Sousa AG, Piotto RF, Pedroso JCM. Mortality risk is dose-dependent on the number of packed red blood cell transfused after coronary artery bypass graft. Rev Bras Cir Cardiovasc 2013; 28 (04) 509-517
    CrossrefPubMedGoogle Scholar
  • 20 Johnson DJ, Scott AV, Barodka VM. et al. Morbidity and mortality after high-dose transfusion. Anesthesiology 2016; 124 (02) 387-395
    CrossrefPubMedGoogle Scholar
  • 21 Karkouti K, Wijeysundera DN, Yau TM. et al. The independent association of massive blood loss with mortality in cardiac surgery. Transfusion 2004; 44 (10) 1453-1462
    CrossrefPubMedGoogle Scholar
  • 22 Rangarajan K, Subramanian A, Pandey RM. Determinants of mortality in trauma patients following massive blood transfusion. J Emerg Trauma Shock 2011; 4 (01) 58-63
    CrossrefPubMedGoogle Scholar
  • 23 Roberts I, Shakur H, Coats T. et al. The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients. Health Technol Assess 2013; 17 (10) 1-79
    CrossrefPubMedGoogle Scholar
  • 24 Gayet-Ageron A, Prieto-Merino D, Ker K, Shakur H, Ageron FX, Roberts I. Antifibrinolytic Trials Collaboration. Effect of treatment delay on the effectiveness and safety of antifibrinolytics in acute severe haemorrhage: a meta-analysis of individual patient-level data from 40 138 bleeding patients. Lancet 2018; 391 (10116): 125-132
    CrossrefPubMedGoogle Scholar
  • 25 Inaba K, Karamanos E, Lustenberger T. et al. Impact of fibrinogen levels on outcomes after acute injury in patients requiring a massive transfusion. J Am Coll Surg 2013; 216 (02) 290-297
    CrossrefPubMedGoogle Scholar
  • 26 Fries D, Martini WZ. Role of fibrinogen in trauma-induced coagulopathy. Br J Anaesth 2010; 105 (02) 116-121
    CrossrefPubMedGoogle Scholar
  • 27 Völzke H, Robinson DM, Kleine V. et al. Preoperative plasma fibrinogen levels predict mortality after coronary artery bypass grafting. Thromb Haemost 2003; 89 (05) 885-891
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 28 Guo S, Dipietro LA. Factors affecting wound healing. J Dent Res 2010; 89 (03) 219-229
    CrossrefPubMedGoogle Scholar
  • 29 Muñoz M, Gómez-Ramírez S, Kozek-Langeneker S. Pre-operative haematological assessment in patients scheduled for major surgery. Anaesthesia 2016; 71 (Suppl. 01) 19-28
    CrossrefPubMedGoogle Scholar
  • 30 Ucar HI, Oc M, Tok M. et al. Preoperative fibrinogen levels as a predictor of postoperative bleeding after open heart surgery. Heart Surg Forum 2007; 10 (05) E392-E396
    CrossrefPubMedGoogle Scholar
  • 31 Yang J-C, Sun Y, Xu C-X. et al. Correlation between red blood cell transfusion volume and mortality in patients with massive blood transfusion: a large multicenter retrospective study. Exp Ther Med 2015; 9 (01) 137-142
    CrossrefPubMedGoogle Scholar
  • 32 Stanworth SJ, Morris TP, Gaarder C. et al. Reappraising the concept of massive transfusion in trauma. Crit Care 2010; 14 (06) R239
    CrossrefPubMedGoogle Scholar
  • 33 Stone GW, Clayton TC, Mehran R. et al. Impact of major bleeding and blood transfusions after cardiac surgery: analysis from the Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial. Am Heart J 2012; 163 (03) 522-529
    CrossrefPubMedGoogle Scholar
  • 34 Sihler KC, Napolitano LM. Complications of massive transfusion. Chest 2010; 137 (01) 209-220
    CrossrefPubMedGoogle Scholar
  • 35 Holcomb JB, Tilley BC, Baraniuk S. et al; PROPPR Study Group. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA 2015; 313 (05) 471-482
    CrossrefPubMedGoogle Scholar
  • 36 Holcomb JB, del Junco DJ, Fox EE. et al; PROMMTT Study Group. The prospective, observational, multicenter, major trauma transfusion (PROMMTT) study: comparative effectiveness of a time-varying treatment with competing risks. JAMA Surg 2013; 148 (02) 127-136
    CrossrefPubMedGoogle Scholar
  • 37 Chee YE, Liu SE, Irwin MG. Management of bleeding in vascular surgery. Br J Anaesth 2016; 117 (Suppl. 02) ii85-ii94
    CrossrefPubMedGoogle Scholar
  • 38 Delaney M, Stark PC, Suh M. et al. Massive transfusion in cardiac surgery: the impact of blood component ratios on clinical outcomes and survival. Anesth Analg 2017; 124 (06) 1777-1782
    CrossrefPubMedGoogle Scholar
  • 39 Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJGM, Lip GYH. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138 (05) 1093-1100
    CrossrefPubMedGoogle Scholar
  • 40 Harder S, Klinkhardt U, Alvarez JM. Avoidance of bleeding during surgery in patients receiving anticoagulant and/or antiplatelet therapy: pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet 2004; 43 (14) 963-981
    CrossrefPubMedGoogle Scholar
  • 41 Kulier A, Levin J, Moser R. et al; Investigators of the Multicenter Study of Perioperative Ischemia Research Group, Ischemia Research and Education Foundation. Impact of preoperative anemia on outcome in patients undergoing coronary artery bypass graft surgery. Circulation 2007; 116 (05) 471-479
    CrossrefPubMedGoogle Scholar
  • 42 Karkouti K, Wijeysundera DN, Beattie WS. Reducing Bleeding in Cardiac Surgery (RBC) Investigators. Risk associated with preoperative anemia in cardiac surgery: a multicenter cohort study. Circulation 2008; 117 (04) 478-484
    CrossrefPubMedGoogle Scholar
  • 43 van Straten AHM, Hamad MA, van Zundert AJ, Martens EJ, Schönberger JPAM, de Wolf AM. Preoperative hemoglobin level as a predictor of survival after coronary artery bypass grafting: a comparison with the matched general population. Circulation 2009; 120 (02) 118-125
    CrossrefPubMedGoogle Scholar